MedTrace Logo

LUCID - LUng Cancer CIrculating Tumour Dna Study

NCT04153526 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 100

Last updated 2019-11-06

No results posted yet for this study

Summary

This is a prospective observational pilot study to investigate levels of circulating tumour DNA (ctDNA) in plasma from patients with stage I to IIIB non-small cell lung cancer (NSCLC) who will undergo treatment with curative intent.

Conditions

  • Non Small Cell Lung Cancer

Interventions

PROCEDURE

Blood sampling

Blood samples will be obtained during routine clinical visits. Ideally, two 9mL blood samples (or equivalent volume) will be collected into EDTA or other appropriate blood collection tube at each time point except at baseline, where three EDTA 9mL tubes and one of 2.6mL (for study of whole blood) will be collected.

PROCEDURE

Surplus Tumour Tissue sample collection from surgery

In surgical patients, lung tumour samples and normal lung tissue will be obtained from surplus tissue removed at the time of surgery. No extra procedures (biopsies or surgeries) are requested for the study.

OTHER

Collection or archival tumour tissue (If available)

Where available surplus tumour and normal tissue from archival tissue will be collected for analysis.

Sponsors & Collaborators

  • Cambridge University Hospitals NHS Foundation Trust

    collaborator OTHER

  • University of Cambridge

    collaborator OTHER

  • CCTU- Cancer Theme

    lead OTHER

Principal Investigators

  • Nitzan Rosenfeld, PhD · CRUK-CI

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-01-31
Primary Completion
2020-02-29
Completion
2020-02-29

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04153526 on ClinicalTrials.gov